Companies Preparing for Expected Cannabis Reclassification Can Now Tap EO Care as Information Resource

EO Care, a leader in clinically guided cannabinoid-based healthcare treatment, announced today that Milliman, a premier global consulting and actuarial firm, completed its methodology review of EO Care’s proprietary cost impact model designed for employers and group plan sponsors to estimate the potential healthcare cost impacts of using evidence-based, clinically guided cannabinoids to mitigate symptoms of cancer, chronic pain, sleep disorders/insomnia, and anxiety. (Click here to review report.)

Milliman’s report concluded that the model EO Care uses to estimate the healthcare cost impact of its clinically-guided cannabinoid-based care program is a reasonable approach.

“Milliman’s review of our theoretical cost impact model methodology for cannabinoid-based treatment could not come at a better time for employers and group plan sponsors,” said Sean Collins, CEO of EO Care. “As momentum builds for the reclassification of cannabis to a less dangerous drug category, companies are looking to get ahead of the curve in responding to the expected rise in employee demand for reimbursement of their cannabinoid-based treatment for selected health issues. Research on cannabis efficacy is limited, but the EO Care cost impact model is a third-party validated model that can estimate potential healthcare impacts for employers and group plan sponsors.”

Noting that the highly respected global risk management firm is known for its careful approach in methodology reviews, Collins observed that the few limitations identified by Milliman in its evaluation report of EO Care’s model to estimate the cost impact of cannabinoid-based treatment stem from the limited availability of actual healthcare claims-based research on cannabis use.

EO Care is on the path to expand its clinically guided cannabinoid-based healthcare treatment services, which includes education, 24/7 evidence-based healthcare guidance, a digital platform of medical cannabinoid products and solutions designed to meet each customer’s needs, and direct delivery to clients.

EO Care’s ground-breaking cost impact model to quantify potential healthcare cost savings from cannabinoids presents a new path forward for employers and payers who are seeking solutions that improve patient outcomes but help manage the costs of healthcare.

“The estimated healthcare cost savings of cannabinoid-based treatment identified by EO Care’s cost impact model are significant,” Collins continued. “Based on these estimates, making cannabinoid-based treatment part of mainstream medicine can deliver benefits to both members and employers/health plans.”

About EO Care

EO Care offers a digital health platform that provides affordable, clinician-created guidance for cannabinoid-based treatments. Its goals are to mainstream and streamline medical cannabinoid use, ensuring clinical responsibility, affordability, and ease of use. EO Care’s digital platform includes general education via a pre-trained Large Language Model (LLM), evidence-based care and prescription models, 24/7 clinical and member support teams available for questions or telemedicine consultations, clinician access platforms and solutions, Visit us at http://eo.care.

Rachel Ford Hutman 310-801-5540 rachel@fordhutmanmedia.com